These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 26862498)

  • 1. Synthetic cannabinoids 2015: An update for pediatricians in clinical practice.
    Castellanos D; Gralnik LM
    World J Clin Pediatr; 2016 Feb; 5(1):16-24. PubMed ID: 26862498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential physiological and behavioral cues observed in individuals smoking botanical marijuana versus synthetic cannabinoid drugs.
    Chase PB; Hawkins J; Mosier J; Jimenez E; Boesen K; Logan BK; Walter FG
    Clin Toxicol (Phila); 2016; 54(1):14-9. PubMed ID: 26653952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Synthetic Cannabinoids Phenomenon.
    Karila L; Benyamina A; Blecha L; Cottencin O; Billieux J
    Curr Pharm Des; 2016; 22(42):6420-6425. PubMed ID: 27655416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ["Spice"--synthetic cannabinoids with dangerous effects].
    Personne M; Westerbergh J; Hammer-Pettersen L
    Lakartidningen; 2014 Nov; 111(47):2105-7. PubMed ID: 25386644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic cannabinoid use: recognition and management.
    Castellanos D; Thornton G
    J Psychiatr Pract; 2012 Mar; 18(2):86-93. PubMed ID: 22418399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective.
    Cohen K; Weinstein AM
    Front Public Health; 2018; 6():162. PubMed ID: 29930934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review.
    Alves VL; Gonçalves JL; Aguiar J; Teixeira HM; Câmara JS
    Crit Rev Toxicol; 2020 May; 50(5):359-382. PubMed ID: 32530350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond THC: The New Generation of Cannabinoid Designer Drugs.
    Fattore L; Fratta W
    Front Behav Neurosci; 2011; 5():60. PubMed ID: 22007163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health.
    Weinstein AM; Rosca P; Fattore L; London ED
    Front Psychiatry; 2017; 8():156. PubMed ID: 28878698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists.
    Marusich JA; Wiley JL; Lefever TW; Patel PR; Thomas BF
    Neuropharmacology; 2018 May; 134(Pt A):73-81. PubMed ID: 29113898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: A case series and review of the literature.
    Armenian P; Darracq M; Gevorkyan J; Clark S; Kaye B; Brandehoff NP
    Neuropharmacology; 2018 May; 134(Pt A):82-91. PubMed ID: 29037744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological and Toxicological Effects of Phytocannabinoids and Recreational Synthetic Cannabinoids: Increasing Risk of Public Health.
    Bukke VN; Archana M; Villani R; Serviddio G; Cassano T
    Pharmaceuticals (Basel); 2021 Sep; 14(10):. PubMed ID: 34681189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of synthetic cannabinoids in patients with psychotic disorders: case series.
    Celofiga A; Koprivsek J; Klavz J
    J Dual Diagn; 2014; 10(3):168-73. PubMed ID: 25392292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic cannabinoid use among college students.
    Mathews EM; Jeffries E; Hsieh C; Jones G; Buckner JD
    Addict Behav; 2019 Jun; 93():219-224. PubMed ID: 30772774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Old and new synthetic cannabinoids: lessons from animal models.
    Zanda MT; Fattore L
    Drug Metab Rev; 2018 Feb; 50(1):54-64. PubMed ID: 29376443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling.
    Liechti M
    Swiss Med Wkly; 2015; 145():w14043. PubMed ID: 25588018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
    Rice J; Cameron M
    Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Synthetic cannabinoids: spread, addiction biology & current perspective of personal health hazard].
    Bonnet U; Mahler H
    Fortschr Neurol Psychiatr; 2015 Apr; 83(4):221-31. PubMed ID: 25893495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of detection frequency and type of synthetic cannabinoids in herbal compounds analyzed by Istanbul Narcotic Department of the Council of Forensic Medicine, Turkey.
    Gurdal F; Asirdizer M; Aker RG; Korkut S; Gocer Y; Kucukibrahimoglu EE; Ince CH
    J Forensic Leg Med; 2013 Aug; 20(6):667-72. PubMed ID: 23910858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic Cannabinoid Abuse in Adolescents: A Case Series.
    Besli GE; Ikiz MA; Yildirim S; Saltik S
    J Emerg Med; 2015 Nov; 49(5):644-50. PubMed ID: 26293411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.